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Materials and Methods: Standard 3D IMRT treatment plans were 
created for 10 NSCLC patients with lymph node involvement based on 
the mid-ventilation phase with a prescribed dose of 66Gy/33F. A CTV 
margin of 1 cm was used around the lymph nodes and was adjusted in 
order to exclude bone tissue and larger blood vessels. Patient-specific 
PTV margins of 0.7-1.0 cm were calculated using a probabilistic 
margin formula and were applied to the CTV. Random day-to-day 
variations of the baseline shift between the primary tumour and the 
CTV-node were simulated by blurring the dose distribution in either 
the cranial-caudal (CC), left-right (LR) or anterior-posterior (AP) 
directions with a Gaussian error distribution. Furthermore, a 
systematic shift between the lymph node and the primary tumour was 
simulated by displacing the dose distribution relative to the 
delineated structures with both 0.25 cm and 0.50 cm. Sufficient dose 
coverage of the involved lymph node was defined as the minimum 
dose (D98%) of the CTV-node was larger than 95% of the prescribed 
dose for 90% of the patients. 
Results: The figure shows the minimum dose of the CTV-node for 90% 
of the patients as a function of the random peak-to-peak variation in 
the CC direction for the different types of simulations. Dose coverage 
was sufficient for all data points above 95% of the prescribed dose, 
which is indicated by the dashed line in the figure. Table 1 
summarises the acceptable random peak-to-peak variations in the CC, 





Conclusions: Dose coverage of the CTV-node can be achieved with 
large random peak-to-peak variations between the primary tumour 
and CTV-node in treatments corrected for daily baseline shift of the 
primary tumour. With the introduction of a systematic shift during the 
treatment course the random peak-to-peak variation was only slightly 
reduced. However, large systematic shifts are undesirable and should 
justify a re-planning of the treatment. 
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Purpose/Objective: 3D position verification in breast radiotherapy 
with kV-CBCT is very accurate but time-consuming, especially in gated 
breast radiotherapy. Due to the need for uniform position verification 
in non-gated and gated conformal breast radiotherapy, the accuracy 
of the patient position adjustment based on the online matching of 
two orthogonal kV fields was investigated. 
Materials and Methods: Twenty breast cancer patients and 20 
patients treated for breast cancer in combination with internal 
mammary-medial supraclavicular (IMMS) lymph node irradiation, i.e. 
locoregional breast treatment, were included in the study. Each 
treatment was performed on a Varian Clinac 2100C/D linear 
accelerator equipped with an amorphous-silicon EPID and an OBI 
system (Varian Medical Systems, Inc.). The patient positioning and 
isocenter shift were checked with online paired kV-kV matching using 
the ribs close to the isocenter. One of the orthogonal kV fields was 
parallel to one of the tangential field directions (see figure). Only 
translations were adjusted. The new patient position was verified 
during 5 fractions by MV imaging of both tangential breast fields and 
kV imaging of the MS-field. All images were matched in Offline Review 
(Varian Medical Systems, Inc.) using bony anatomy. The differences 
for each tangential field were reported as ΔCLD (Central-Lung-
Distance, i.e. the distance between the deep field edge and the 
interior chest wall at field central axis), and ΔC(ranio)C(audal). The 
differences for the MS-field were reported as ΔVrt, i.e. ΔVertical, ΔCC 
and ΔLat(eral). The range of the patient mean errors, the percentage 
of the patient population with an absolute value of the mean error 
larger than 2mm, the population mean, population systematic error 
and population random error were reported. 
Results: For breast cancer treatment with and without IMMS 
irradiation, a mean CLD error ranging from -1mm to 2mm and from -
1mm to 3mm, respectively, was found. Only 5% of the breast cancer 
patients had a mean ΔCLD > 2mm. The patient mean ΔCC ranged from 
-3mm to 3mm and from 0mm to 3mm for the breast treatments and 
the locoregional breast treatments, respectively. For 10% of the 
patients, the mean ΔCC was larger than 2mm, irrespective of the 
treatment. None of the population systematic errors were larger than 
1mm and none of the population random errors were larger than 
2mm, irrespective of the patient group (see table). The population 
systematic and random errors measured in the MS-field were smaller 
than 1mm for all three directions (see table). 
 
 
Conclusions: The new position verification protocol is appropriate for 
accurate, uniform and quick 3D position verification in non-gated 
(locoregional) breast radiotherapy and easily extendible to gated 
breast radiotherapy. An important property of the protocol is the low 
imaging dose to both the target volume and the healthy tissue thanks 
to the combination of the kV imaging and the field orientation. 
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Purpose/Objective: Uncertainties in patient positioning are a crucial 
issue to be considered when treating patients with particles. In this 
study we aim to quantify the effect of small patient misalignment for 
different proton dose delivery techniques.  
Materials and Methods: We have investigatedthree different delivery 
techniques: 3D spot-scanning (3DSS), distal edge tracking(DET) and 
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isocentric rotational delivery (DIR) where the gantry moves to 
multiple positions and delivers a ray of spots with various energies 
from each fixed gantry position without lateral beam scanning. A 
cylindrical water phantom with a cylindrical target (3.3cm length, 
5cm diameter) in the middle of the phantom has been chosen. For 
3DSS also a lung tumour patient case has been evaluated. For both 
cases a dose of 60Gy was prescribed to the CTV in a single fraction. 
Spot positions and weights were derived and the dose was 
recalculated with a dose calculation algorithm. For each delivery 
method and case two plans were derived: one with the isocenter (IC) 
positioned in the middle of a CT-voxel andone with the IC shifted by 
0.4 (0.3)mm (CT grid: Δx=Δy=Δz=1mm) for the cylinder phantom 
(patient) relative to the IC in each direction simulating a small setup 
error. 
Results: Table 1 summarizes the minimal doses to 1%, 50% and 95% of 
the target. The most robust method shows to be the 3DSS. Particularly 
for the water phantom the dose differences are minor. However, this 
is not valid for the patient case. Here, even with 3DSS the minimal 
dose to 95% of the volume was reduced by almost 3Gy due to the IC 
shift. Furthermore, local dose differences up to almost 8% within the 
target and 3mm distant (cc direction) to the IC were found. Generally, 
the dose differences between the two plans are most obvious within 
the gradient region. The DET methodis less robust. The general trend 
is the same as for the 3DSS case but absolute local differences are up 
to almost 5Gy at 14mm distant from the IC slice. With this technique 
the dose differences are mainly in the gradient region of the dose 
distribution. The DIR method is most sensitive to the setup-errors, 
where the beam rotates around the IC without lateral scanning. The IC 
shift therefore shifts the dose distribution in the same direction for all 
beams. Therefore, the detrimental effects can accumulate. Dose 
differences for the two plans are up to 7% even within the IC slice. 
 
Conclusions: The results show that even very small setup errors that 
cannot be completely avoided through image guidance can influence 
the resulting dose distributions depending on the delivery method for 
proton therapy. However, the presented results assume a single 
fraction delivery which is not the usual clinical practice but illustrates 
the effect best. For fractionated treatment the effects should be 
reduced, however, based on the presented results, studies evaluating 
the residual effects with particular respect to the applied delivery 
technique are required. 
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Purpose/Objective: IMRT and VMAT for RT of pancreatic cancer can 
reduce toxicity to OARs such as stomach, small intestines and kidneys, 
but the tight conformity of the high-dose surface to the target area in 
these techniques requires highly accurate positioning. Daily cone-
beam CT (CBCT) enables pretreatment correction of patient setup 
errors. The pancreas shows considerable day-to-day positional 
variation relative to the vertebrae, which can introduce substantial 
systematic and random setup errors. The use of intratumoral fiducial 
markers, visible on CBCT, can help reduce the setup errors and 
decrease the currently large PTV. The aim of our study is to quantify 
interfractional variation in tumor position using fiducials and CBCT 
and thus determine the potential benefit of using intratumoral 
fiducials rather than bony anatomy for daily pancreatic patient setup 
verification.  
Materials and Methods: Eleven consecutive pancreatic cancer 
patients were included in our study and each received 2 to 3 gold 
fiducial markers (Visicoil; 0.35 mm diameter) by endoscopic 
ultrasound-guided implantation. The two markers of one patient could 
later not be located on the reference CT. In the other 10 patients, a 
total of 25 markers were visible on the CT as well as on all CBCTs. For 
these patients, who received 25 × 2Gy, a total of 242 CBCTs were 
registered with the reference CT on bony anatomy and on each of the 
markers. From this, the displacement of markers relative to the 
vertebrae was determined, as well as the distance between marker 
pairs. Marker migration, tissue deformation and marker localization 
error all affect the distance between two markers. To validate the use 
of the fiducial markers as indicator of tumor position, we analyzed the 
20 marker pair distances using linear fits to the CBCT data.  
Results: Pair distances showed only slight trends (mean slope of -0.03 
mm/day, range -0.10 to 0.02 mm/day, 5/20 with p<0.05), most likely 
due to tissue deformation (shrinkage), but no clear shifts that would 
indicate marker migration. The residuals of the linear fits had a mean 
SD of 0.8 mm (range 0.4–1.3 mm), a measure for localization error. 
From the positional variation, we found for these ten patients an SD 
of systematic error Σ of 4.0, 5.3 and 3.6 mm and an SD of random 
error σ of 3.6, 4.9, and 2.3 mm, in LR, SI and AP, respectively. See 
the Figure for the distributions in the SI-direction.  
 
  
For 11% (26/242) of fractions, the vector displacement relative to 
bony anatomy was >15mm; 29% (69/242) showed a vector 
displacement >10mm. For one patient the vector displacement for 
72% (18/25) of fractions was >10mm.  
Conclusions: This study of interfractional variation of pancreatic 
tumor position shows large mean displacements (systematic errors) in 
addition to a wide spread in positional range between patients. This 
strongly supports the benefit of on-line position verification based on 
the tumor itself rather than on bony anatomy, and hence the 
necessity of implantation of intratumoral fiducial markers. 
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Purpose/Objective: In the context of dose accumulation in prostate 
IGRT, most proposed methods assume that the fraction dose can be 
approximated by a propagation of the planned dose. The objectives of 
this study were to quantify the uncertainties resulting from this 
approximation.  
 
 
 
 
 
 
 
